Haematospermia
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Haematospermia
Fasting laboratory tests
- Blood FBC
- Serum electrolytes (basic biochemistry)if needednon-French guidelineThe EAU 2023 algorithm cites a “serum biochemistry panel” in the initial tests, without detailing its content [3]; a 2017 review mentions routine clinical chemistry [1]; the EAU 2026 text cites FBC, liver function tests and haemostasis, without electrolytes [2]. To be requested if a basic biochemistry panel is wanted in addition to FBC and haemostasis.
- PT, aPTT
- ASTif needednon-French guidelineThe EAU 2026 cites liver function tests with FBC and haemostasis to detect systemic disease (chronic liver disease, haemostasis disorders); the EAU 2023 algorithm speaks of a “serum biochemistry panel” without detailing it [2,3].
- ALT (liver function tests, looking for a systemic disease)if needednon-French guidelineThe EAU 2026 cites liver function tests with FBC and haemostasis to detect systemic disease (chronic liver disease, haemostasis disorders); the EAU 2023 algorithm speaks of a “serum biochemistry panel” without detailing it [2,3].
- Total PSA (man over 40, after information)if needednon-French guidelineThe EAU recommends screening for prostate cancer (PSA and digital rectal examination) in men aged 40 or over with persistent haemospermia (weak recommendation) [3]; in 2026 PSA is to be measured in men over 40 who have been informed about this test [2]. A 2017 review also recommends PSA after age 40 [1]. See the page “PSA: request for prostate cancer screening and raised PSA”.
- Semen analysisif needednon-French guidelinePersistent haemospermia or doubt about the nature of the blood: the EAU 2023 algorithm includes semen analysis in the initial tests [3]; a 2017 review advises examining the ejaculate under the microscope whenever possible, to distinguish true haemospermia from discolouration due to something else [1]. The EAU 2026 text requests it only if tuberculosis or schistosomiasis is suspected (return from an endemic area) [2].
On urine tests
- Urine microscopy and culture
STI tests
- HIV serology (if never screened or exposure)if neededThe EAU includes STI screening in the initial tests for haemospermia, without listing the serologies [2,3]. The French College of General Medicine proposes STI screening for an asymptomatic patient if never done, after a change of partner, in case of doubt about the partner or after unprotected sex with a casual partner; HIV serology is reliable 6 weeks after the last risk exposure [4].
- Syphilis serology (if never screened or exposure)if neededThe EAU includes STI screening in the initial tests for haemospermia, without listing the serologies [2,3]. It is in the French College of General Medicine's standard STI screening prescription, with the same indications as HIV serology [4].
- Hepatitis C serology (if exposure)if neededThe EAU includes STI screening in the initial tests for haemospermia, without listing the serologies [2,3]. The French College of General Medicine adds it as an option to the standard STI screening prescription; it is reliable 3 months after the last risk exposure [4].
- Hepatitis B serology (HBsAg, anti-HBs, anti-HBc) (if never screened or exposure)if neededThe EAU includes STI screening in the initial tests for haemospermia, without listing the serologies [2,3]. The French College of General Medicine places it in the standard STI screening prescription (HBsAg, anti-HBs, anti-HBc); it is reliable 3 months after the last risk exposure [4].
On first-void urine or self-collected sample
- Chlamydia trachomatis and Neisseria gonorrhoeae NAAT (PCR) on first-void urine (if exposure)if neededFor haemospermia, the EAU 2026 asks for full STI screening on first-void urine, serum and genitourinary samples, with testing for Chlamydia, Ureaplasma and herpes [2]. The French College of General Medicine proposes, as screening in an asymptomatic patient, Chlamydia and gonorrhoea PCR on first-void urine, with “asymptomatic” stated on the prescription [4].
- Chlamydia and gonococcus NAAT (PCR) on additional samples (throat, anus) depending on sexual practices and exposureif neededSeveral sites can be sampled according to the practices declared and exposure: urine (first-void), throat (pharyngeal swab), anus (self-collected anal swab) [4]. The fee schedule covers testing at 2 or 3 sites (procedures 5302 and 5303) on explicit prescription, in case of anal or pharyngeal sex [5].
Sources (10)
- Mathers MJ, Degener S, Sperling H, Roth S. Hematospermia — a symptom with many possible causes. Dtsch Arztebl Int 2017;114(11):186-191.
- European Association of Urology. EAU Guidelines on Sexual and Reproductive Health, édition 2026 (mise à jour limitée de 2025), chapitre 6 « Disorders of ejaculation », section 6.8 « Haemospermia ».
- EAU GUIDELINES ON SEXUAL AND REPRODUCTIVE HEALTH
- Collège de la Médecine Générale. Les IST en pratique, hors VIH et VHB (kit santé sexuelle en médecine générale), mars 2025.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 5301, 5302, 5303 (amplification génique de Chlamydia trachomatis et Neisseria gonorrhoeae, 1, 2 ou 3 sites).
- Stefanovic KB, Gregg PC, Soung M. Evaluation and treatment of hematospermia. Am Fam Physician. 2009;80(12):1421-7.
- Dantanarayana N. Haematospermia. Aust Fam Physician. 2015;44(12):907-10.
- Expert Panel on Urological Imaging ; Harmath C, Allen BC, Turkbey B, et al. ACR Appropriateness Criteria Hematospermia. J Am Coll Radiol. 2025;22(11S):S539-S549.
- National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral (NG12). 2015, dernière mise à jour le 15 avril 2026 ; chapitres par site de cancer et par symptôme.
- National Health Service (Royaume-Uni). Blood in semen. Page revue le 23 septembre 2025.